{"product_id":"dexcom-bcg-matrix","title":"DexCom Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDexCom’s BCG Matrix snapshot highlights its continuous innovation in CGM systems and identifies which product lines are likely Stars or Cash Cows versus slower-growth offerings; understanding these placements clarifies where management should invest or divest. This preview outlines market share and growth dynamics but the full BCG Matrix delivers quadrant-by-quadrant data, actionable recommendations, and ready-to-use visuals. Purchase the complete report to get a Word analysis plus an Excel summary that speed-translates insights into strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G7 Global Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe G7 system is Dexcom’s primary growth driver by late 2025, holding roughly 55% share of the intensive insulin-delivery CGM segment and driving 2025 product revenue growth of ~18% year-over-year to $3.2B.\u003c\/p\u003e\n\u003cp\u003eIts 30-minute warm-up and MARD ~7% have outpaced rivals, helping global shipments rise 26% in 2024–25 and expanding presence in 24 new markets. \u003c\/p\u003e\n\u003cp\u003eDexcom increased R\u0026amp;D and SG\u0026amp;A spend to $1.1B in 2025, funding marketing and pivotal trials to defend leadership versus Abbott and Medtronic. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStelo Glucose Biosensor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaunched in 2023 to target the 400+ million global Type 2 non-insulin market, Stelo Glucose Biosensor became a star by late 2025 with estimated 2025 retail sales of $220M and 35% month-on-month unit growth among OTC buyers.\u003c\/p\u003e\n\u003cp\u003eIt serves health-conscious consumers and early-stage diabetics, capturing ~12% share of OTC CGM units in the US by Q4 2025 while conversion-to-subscription rates hit 18%.\u003c\/p\u003e\n\u003cp\u003eHigh promotional spend (approx $60M in 2025) pressures margins short-term, but unit economics (LTV\/CAC ~3.5x) and rapid scale point to material cash generation from 2026 onward.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Insulin Delivery Integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom’s automated insulin delivery integrations with pump makers Tandem (Tandem Diabetes Care) and Insulet (Insulet Corporation) position its G6\/G7 sensors as the ecosystem brain, supporting ~60–70% share of U.S. closed‑loop systems as of 2025 and driving rapid user growth (~25% YoY in automated users through 2024).\u003c\/p\u003e\n\u003cp\u003eThis segment sits in BCG's Stars: high market share and high growth; it burns R\u0026amp;D and regulatory cash for firmware and interoperability but offers outsized strategic value—contributing an estimated 20–25% of device revenues and improving lifetime customer retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexCom is treating International Emerging Markets (Latin America, SEA, parts of South Asia) as Stars: high-growth diabetes prevalence (+8–10% annual cases regionally; IDF 2025) and rising CGM adoption give DexCom strong early-mover potential as it builds brand and payer relationships.\u003c\/p\u003e\n\u003cp\u003eDexCom is committing heavy capex and opex for local distribution, regulatory approvals, and training—estimated multi-year investment of $200–350M to scale in key markets—so market share gains hinge on sustained spend and local partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: regional diabetes incidence +8–10% (IDF 2025)\u003c\/li\u003e\n\u003cli\u003eEarly mover edge: limited established CGM brands in many countries\u003c\/li\u003e\n\u003cli\u003eRequired spend: $200–350M multi-year deployment\u003c\/li\u003e\n\u003cli\u003eFocus: distribution, regulatory, clinician\/patient education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom Clarity Data Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexcom Clarity Data Platform has evolved into a leading data-management tool, delivering actionable insights to patients and providers and supporting over 2.1 million active users worldwide as of Q4 2025.\u003c\/p\u003e\n\u003cp\u003eIn the high-growth digital-health analytics market (CAGR ~16% through 2028), Clarity sustains high engagement and a double-digit share of Dexcom ecosystem users, driving recurring device stickiness and higher lifetime value.\u003c\/p\u003e\n\u003cp\u003eThe platform acts as a critical retention hook, so Dexcom must keep investing—estimated $120–160M annual spend—in software engineering and cybersecurity to protect PHI and sustain regulatory compliance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.1M active users Q4 2025\u003c\/li\u003e\n\u003cli\u003eDigital-health analytics CAGR ~16% to 2028\u003c\/li\u003e\n\u003cli\u003e$120–160M estimated annual platform spend\u003c\/li\u003e\n\u003cli\u003eDrives device stickiness and higher LTV\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Stars Propel $3.2B G7 Growth—Clarity 2.1M Users, $1.1B R\u0026amp;D+SG\u0026amp;A Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eG7\/G6 sensors, Stelo OTC, international expansion, and Clarity sit in BCG Stars: high market share and high growth, driving ~20–25% of device revenue and ~18% product revenue growth to $3.2B in 2025 while burning R\u0026amp;D\/market spend (~$1.1B R\u0026amp;D+SG\u0026amp;A; $60M Stelo promos; $200–350M intl capex). Clarity: 2.1M users; $120–160M annual platform spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice revenue share from Stars\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7-driven product rev\u003c\/td\u003e\n\u003ctd\u003e$3.2B (18% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D+SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelo retail\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClarity users\u003c\/td\u003e\n\u003ctd\u003e2.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl scale spend\u003c\/td\u003e\n\u003ctd\u003e$200–350M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for DexCom: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page DexCom BCG Matrix mapping products by growth and share for quick strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G6 Mature Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Dexcom G6 remains a cash cow, generating an estimated $2.1 billion in 2025 revenue and serving ~1.2 million active users who have not yet moved to newer models.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D for G6 was amortized years ago, so sensor and transmitter gross margins exceed 60%, giving exceptionally high cash conversion.\u003c\/p\u003e\n\u003cp\u003eThat steady free cash flow—about $800 million in 2025—funds development of next‑gen continuous glucose monitors and biosensors, cutting time‑to‑market risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eType 1 Diabetes Core Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexComs Type 1 diabetes core market is a mature, high-share segment: as of fiscal 2024 DexCom held about 50%–55% U.S. CGM market share in Type 1 patients, with strong brand loyalty and multi-year retention rates above 70% annually.\u003c\/p\u003e\n\u003cp\u003eGrowth is steady, not rapid—Type 1 patient CGM penetration rose ~3–4 percentage points yearly in the U.S. in 2023–24—so this segment functions as a cash cow needing less defensive marketing spend.\u003c\/p\u003e\n\u003cp\u003eRecurring revenue from durable users drove 2024 subscription-like sales stability, contributing to \u0026gt;60% of recurring revenue and helping DexCom service debt and fund R\u0026amp;D; FY2024 revenue was $3.4 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Government Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom (DexCom, Inc.) secured Medicare coverage for continuous glucose monitoring (CGM) in 2020 and by 2025 reports over 350,000 Medicare beneficiaries using its devices, supporting recurring revenue of roughly $500m–$700m annually from U.S. public payers alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Channel Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe shift from durable medical equipment to pharmacy channels has cut distribution friction for DexCom, improving cash conversion: pharmacy fills now cover an estimated 65–70% of U.S. retail CGM prescriptions (2025 data), shortening payment cycles and reducing accounts receivable days.\u003c\/p\u003e\n\u003cp\u003eThis mature pharmacy model needs less admin overhead and broader patient access—millions gain same-day pickup at \u0026gt;20,000 retail locations—so operating costs per unit fall versus DME logistics.\u003c\/p\u003e\n\u003cp\u003eHigh retail market share lets DexCom collect passive gains with minimal capex; incremental revenue from pharmacy penetration grew ~12% YoY in 2024 without major new infrastructure spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePharmacy fills ~65–70% of U.S. CGM scripts (2025)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;20,000 retail pickup locations\u003c\/li\u003e\n\u003cli\u003e2024 incremental pharmacy revenue +12% YoY\u003c\/li\u003e\n\u003cli\u003eLower AR days and reduced admin per unit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Subscription Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy late 2025 Dexcom’s direct-to-consumer subscription billing for long‑term continuous glucose monitor (CGM) users has become a low-cost, high-margin cash cow, producing predictable revenue—subscriptions represented about 42% of U.S. recurring revenue and grew at ~18% YoY in 2024–25.\u003c\/p\u003e\n\u003cp\u003eLow incremental marketing spend cut churn to ~8% annualized and raised lifetime value (LTV) by roughly 25%, while subscriber telemetry trimmed supply-chain costs, improving gross margins by ~220 basis points versus non‑subscribed sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubscriptions = 42% of U.S. recurring revenue (late 2025)\u003c\/li\u003e\n\u003cli\u003eYoY subscription growth ~18% (2024–25)\u003c\/li\u003e\n\u003cli\u003eChurn ≈ 8% annualized; LTV +25%\u003c\/li\u003e\n\u003cli\u003eSupply-chain margin improvement ≈ 220 bps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom’s G6: $2.1B revenue, $800M FCF — subscription-powered cash machine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom’s G6 and subscription base are cash cows: ~$2.1B revenue (2025), ~$800M free cash flow (2025), \u0026gt;60% gross margins on sensors, subscriptions ≈42% of U.S. recurring revenue and ~8% churn, pharmacy fills 65–70% of scripts supporting predictable, low‑capex cash generation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eG6 revenue\u003c\/td\u003e\n\u003ctd\u003e$2.1B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003e$800M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor gross margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscriptions share\u003c\/td\u003e\n\u003ctd\u003e42% U.S. recurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChurn\u003c\/td\u003e\n\u003ctd\u003e~8% annual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy fills\u003c\/td\u003e\n\u003ctd\u003e65–70% U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eDexCom BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact DexCom BCG Matrix you'll receive after purchase—no watermarks, no draft notes—just a fully formatted, analysis-ready report designed for strategic use by investors and corporate teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747895521657,"sku":"dexcom-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dexcom-bcg-matrix.png?v=1772202685","url":"https:\/\/growthsharematrix.com\/products\/dexcom-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}